> Back to seminars list


Tuesday, June 7th, 2022
Centre de recherche - Paris - Amphithéâtre Marie Curie

Dissecting and modulating reactive anti-tumor immunity in human cancers

Reinvigoration of tumor-specific T cells by cancer immunotherapies, in particular PD-1/PD-L1 blocking agents, has been the most important innovation in the treatment of patients with cancer. Nevertheless, durable clinical benefit is currently limited to a small number of patients. At present, the immunological alterations that occur in human cancers upon PD-1 blockade are not well understood. Using patient-derived organotypic tumor models, we investigate how tumor immune composition and architecture influence immunotherapy response and how distinct treatments can change immune activity in a tumor. The observed immunotherapy-induced changes can then be linked to the inherent qualities of a tumor and its infiltrating immune populations, thereby contributing to the identification of determinants for effective response to immunotherapy and to the development of novel treatment strategies.


Dr. Daniela Thommen

Netherlands Cancer Institute - Amsterdam, Netherlands

Invited by

Christina Metoikidou
Immunité et cancer (U932)

Institut Curie

Sebastian Amigorena
Immunité et cancer (U932)

Institut Curie

Learn more

Daniela Thommen is a Junior Group Leader at the Netherlands Cancer Institute. She
received her MD and PhD from the University of Basel, Switzerland. She then trained in internal medicine and medical oncology in Switzerland. In parallel to her clinical
specialization, she worked as a research fellow in the lab of Prof. Alfred Zippelius at the Department Biomedicine in Basel investigating the role of intratumoral T cell heterogeneity for response to immune checkpoint blockade in human lung cancer. In 2016, she joined the lab of Prof. Ton Schumacher at the Netherlands Cancer Institute with a postdoctoral fellowship from the Swiss National Science Foundation, where she focused on developing human tumor explant models to study patient-specific immunotherapy responses ex vivo. In 2020, Daniela Thommen became an independent Junior group leader at the Netherlands Cancer Institute. Her research focuses on understanding the role of intratumoral immune cell heterogeneity for immunotherapy response and on the development of novel biomarkers and personalized immunotherapy strategies using patient-derived organotypic models. Daniela Thommen is the recipient of a 2018 Bas Mulder Award from the Dutch Cancer Society and of the 2019 Swiss Pfizer Research Prize in Oncology.